JCAR 020

Drug Profile

JCAR 020

Alternative Names: JCAR020; MUC-16 directed/IL-12 armored T cell therapy - Juno Therapeutics

Latest Information Update: 13 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Juno Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Ovarian cancer

Most Recent Events

  • 07 Jan 2016 Juno Therapeutics and Memorial Sloan Kettering Cancer Center enters into an exclusive license agreement with Eureka Therapeutics for use of a fully-human MUC16 binder in CAR T cell immunotherapy
  • 10 Nov 2015 Preclinical trials in Ovarian cancer in USA (Parenteral)
  • 10 Nov 2015 The US FDA approves IND application for MUC-16/IL-12 in Ovarian cancer (recurrent)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top